This inventor holds 2 USPTO granted patents. Top assignees: Euro-Celtique S.a., Societe Cortial, S.a.. Active years: 1988-1989.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1988-1989
Title: Rosa Martani: Innovator in Pharmaceutical Compositions
Introduction
Rosa Martani is a notable inventor based in Bordeaux, France. She has made significant contributions to the field of pharmaceuticals, particularly in the development of controlled release compositions. With a total of 2 patents, her work has the potential to enhance drug delivery systems.
Latest Patents
Rosa Martani's latest patents include a "Controlled release pharmaceutical composition" and a "Method of producing slow-release pharmaceutical forms." The first patent describes a solid, controlled release pharmaceutical composition that offers enhanced control over drug release. This composition includes an acid addition salt or a quaternary ammonium salt of an organic base drug complexed with an anionic surfactant, all distributed in a hydrophilic polymer matrix. The second patent outlines a novel method for producing slow-release pharmaceutical forms administered orally. This method employs two anionic resins in variable proportions, allowing for the modification of release kinetics of active principles.
Career Highlights
Throughout her career, Rosa has worked with reputable companies such as Euro-Celtique S.A. and Société Cortial S.A. Her experience in these organizations has contributed to her expertise in pharmaceutical innovations.
Collaborations
Rosa has collaborated with notable coworkers, including Elisabeth Le Huede and Jeanne Dumas. These partnerships have likely enriched her research and development efforts in the pharmaceutical field.
Conclusion
Rosa Martani's contributions to controlled release pharmaceutical compositions demonstrate her innovative spirit and dedication to improving drug delivery systems. Her patents reflect a commitment to advancing pharmaceutical technology, which can significantly impact patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile